(S)-1-(4-吡啶基)乙胺 | 27854-96-2

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (S)-1-(4-吡啶基)乙胺
• 英文名称: (S)-1-(4-pyridyl)ethylamine
• 英文别名: (S)-1-(pyridin-4-yl)ethanamine；(1S)-1-(4-pyridinyl)ethylamine；(S)-pyridin-4-yl-ethylamine；(1S)-α-methyl-4-pyridinemethanamine；(1S)-1-pyridin-4-ylethanamine
• CAS: 27854-96-2
• 化学式: C₇H₁₀N₂
• mdl: MFCD09256819
• 分子量: 122.17
• InChiKey: HIZMJYQEHFJWQY-LURJTMIESA-N

物化性质

• 沸点：
  221.1±15.0 °C(Predicted)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 储存条件：
  存储条件：2-8℃，避光保存，在惰性气体环境中保持。

反应信息

• 作为反应物：
  描述：

  (S)-1-(4-吡啶基)乙胺 在 盐酸 、 platinum(IV) oxide 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 生成 2-trimethylsilylethyl N-[(1S)-1-piperidin-4-ylethyl]carbamate
  参考文献：
  名称：

  IMIDAZOPYRIMIDINE DERIVATIVES

  摘要：

  本公开提供了一种如下式（I）的化合物： 或其药学上可接受的盐。本公开还提供了包含如下式I的化合物的药物组合物，制备如下式I的化合物的方法，以及治疗癌症的治疗方法。

  公开号：

  US20200108071A1
• 作为产物：
  描述：

  (R)-(+)-1-(4-吡啶基)乙醇 在 palladium on activated charcoal 正丁基锂 、 sodium azide 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 六甲基磷酰三胺 、 正己烷 为溶剂， 反应 2.08h， 生成 (S)-1-(4-吡啶基)乙胺
  参考文献：
  名称：

  3- and 4-Pyridylalkyl Adamantanecarboxylates:  Inhibitors of Human Cytochrome P450_17α (17α-Hydroxylase/C_17,20-Lyase). Potential Nonsteroidal Agents for the Treatment of Prostatic Cancer

  摘要：

  Various 3- and 4-pyridylalkyl 1-adamantanecarboxylates have been synthesized and tested for inhibitory activity toward the 17 alpha-hydroxylase and C-17,C-20-lyase activities of human testicular cytochrome P450(17 alpha). The 4-pyridylalkyl esters were much more inhibitory than their 3-pyridylalkyl counterparts. The most potent was (S)-1-(4-pyridyl)ethyl 1-adamantanecarboxylate (3b; IC50 for lyase, 1.8 nM), whereas the (R)-enantiomer 3a was much less inhibitory (IC50 74 nM). Nearly as potent as 3b was the dimethylated counterpart, the 2-(4-pyridylpropan-2-yl) ester 5 (IC50 2.7 nM), which was also more resistant to degradation by esterases. In contrast to their 4-pyridyl analogs, the enantiomers of the 1-(3-pyridyl)ethyl ester were similarly inhibitory (IC50 for lyase; (R)-isomer 8a 150 nM, (S)-isomer 8b 230 nM). Amides corresponding to the 4-pyridylmethyl ester 1 and the (S)-1-(4-pyridyl)ethyl ester 3b, respectively 11 and 15b, were much less inhibitory than their ester counterparts. On the basis of a combination of inhibitory potency and resistance to esterases, the ester 5 was the best candidate for further development as a potential nonsteroidal inhibitor of cytochrome P450(17 alpha), for the treatment of prostate cancer.

  DOI：

  10.1021/jm950749y

文献信息

• Transaminases Applied to the Synthesis of High Added-Value Enantiopure Amines
  作者：Caroline E. Paul、María Rodríguez-Mata、Eduardo Busto、Iván Lavandera、Vicente Gotor-Fernández、Vicente Gotor、Susana García-Cerrada、Javier Mendiola、Óscar de Frutos、Iván Collado

  DOI：10.1021/op4003104

  日期：2014.6.20

  stereoselective amination of (hetero)aromatic ketones using transaminases have been studied, such as temperature, pH, substrate concentration, cosolvent, and source and percentage of amino donor, to further optimize the production of enantiopure amines using both (S)- and (R)-selective biocatalysts from commercial suppliers. Interesting enantiopure amino building blocks have been obtained, overcoming some limitations

  研究了使用转氨酶影响（杂）芳族酮的立体选择性胺化的关键参数，例如温度，pH，底物浓度，助溶剂以及氨基供体的来源和百分比，以进一步优化同时使用这两种方法生产对映体纯胺的方法（S） -和（R）选择性生物催化剂来自商业供应商。已经获得了有趣的对映纯氨基结构单元，克服了传统化学合成方法的某些局限性。扩大代表性方法的规模，提供对映体纯形式的卤代和杂芳族胺，分离产率高。
• Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
  申请人：Tegley Christopher

  公开号：US20050054670A1

  公开（公告）日：2005-03-10

  Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如介导血管生成的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，用于预防和治疗涉及癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在此类方法中有用的中间体。
• [EN] COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DU RÉCEPTEUR A2B DE L'ADÉNOSINE ET DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2019046784A1

  公开（公告）日：2019-03-07

  Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors. In an aspect is provided a method of inhibiting Adenosine A2B Receptor activity and Adenosine A2A Receptor activity, the method including contacting the Adenosine A2B Receptor and Adenosine A2A Receptor with a compound as described herein, including embodiments.

  在此披露的内容包括调节腺苷受体的组合物和方法。在一个方面，提供了一种抑制腺苷A2B受体活性和腺苷A2A受体活性的方法，该方法包括将腺苷A2B受体和腺苷A2A受体与本文描述的化合物接触，包括各种实施方式。
• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：COURTNEY STEPHEN MARTIN

  公开号：WO2013033068A1

  公开（公告）日：2013-03-07

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用可接受载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用。还提供了筛选能够抑制KMO活性的化合物的方法。
• [EN] CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS<br/>[FR] COMPOSES HETEROCYCLIQUES CONDENSES UTILISES COMME AGONISTES DE LA CALCITONINE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003076440A1

  公开（公告）日：2003-09-18

  The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions which are related to irregular calcification.

  本发明涉及新型融合杂环环系统化合物及其在治疗和预防与不规则钙化相关的疾病或症状中的应用方法。